Business Daily from THE HINDU group of publications
Saturday, Mar 15, 2008
ePaper | Mobile/PDA Version
Business Daily from THE HINDU group of publications Saturday, Mar 15, 2008 ePaper | Mobile/PDA Version |
|
|
|
|
|
|
|
Corporate
-
Announcements Marketing - Strategy Intas Biopharma forms new sales divisions
As part of new sales strategy, IBPL has doubled its sales force to allow more focussed approach towards niche therapeutic areas of oncology. Our Bureau Ahmedabad, March 14 Intas Biopharmaceuticals Ltd (IBPL) has announced the formation of three new sales divisions, namely Track, Aqua and Relay, to focus on the company’s product baskets. The divisions would take care of sales and marketing of biotech drugs, oncology as well as plasma products that cater to solid tumours, haematology and supportive therapies respectively. The segregation of sales divisions, based on therapeutic segments, is aimed at increasing focus and penetration of oncology products in the domestic market, the Ahmedabad-based company said in a statement here. Mr Simon Daniel, Chief Executive (Marketing), said that in order to give an impetus to IBPL’s sales activities, the company plans to launch this calendar year one more new division — Bridge, catering to nephrology/neurology therapeutic areas. As part of new sales strategy, IBPL has doubled its sales force to allow more focussed approach towards niche therapeutic areas of oncology. Additionally, the new division Aqua will look after sales activity of plasma products namely Albumin and Globucel, marketed through Celestial Biologicals, an associate company of IBPL. Intas, which entered the Indian anti-cancer market in 1998, now boasts of one of the most comprehensive oncology product basket comprising of 26 products in different dosage forms (capsules, injections, tablets and pre-filled syringes). He said IBPL is the only biotech company to manufacture Pegylated G-CSF in India and simultaneously market the product under the brand name Neupeg. The product offers treatment against toxicity caused due to chemotherapy in cancer patients. This USP has prompted the need for a special and dedicated sales division, Relay. As per market estimates, there lies immense untapped potential in Indian oncology segment. More Stories on : Announcements | Strategy | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
 |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2008, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|